Table 2.
Outcomes of Infusions on Patients With Locally Advanced Nonmelanoma Cutaneous Malignancies After an ILI (Stratified by Extremity Type)
| Characteristic | Overall (N = 26) | Upper Limb (n = 10) | Lower Limb (n = 16) | P Value |
|---|---|---|---|---|
| Limb volume, median (IQR) | 5.6 (2.8 to 7.0) | 2.3 (1.7 to 2.9) | 6.6 (5.6 to 7.2) | .001 |
| Melphalan dose, median (IQR), mg | 31.0 (20.0 to 42.0) | 19.0 (15.0 to 26.0) | 41.1 (34.0 to 46.0) | .001 |
| Actinomycin D dose, median (IQR), μg | 370 (200 to 470) | 200 (160 to 280) | 450 (385 to 680) | .002 |
| Dose adjusted for corrected ideal body weight, % | 77 | 70 | 81 | .51 |
| Papaverine use intraoperatively, % | 73 | 70 | 75 | .78 |
| Ischemia time, median (IQR), min | 56 (49 to 77) | 56 (50 to 71) | 57 (49 to 83) | .53 |
| Perfusate blood gas, 30 min | ||||
| Base excess, median (IQR), mEq | −10.1 (−14.7 to −6.9) | −14.4 (−14.9 to −10.1) | −8.2 (−12.1 to −3.8) | .07 |
| PaO2, median (IQR), mm Hg | 12.0 (5.6 to 18.0) | 15.0 (11.0 to 18.0) | 9.0 (5.0 to 17.0) | .13 |
| pH, median (IQR) | 7.12 (7.08 to 7.21) | 7.08 (7.06 to 7.10) | 7.18 (7.10 to7.22) | .01 |
| Peak CPK, median (IQR), U/mL | 93 (69 to 2292) | 127 (69 to 2479) | 93 (65 to 2292) | .78 |
| Day of peak of CPK, median (IQR) | 3.0 (2.0 to 6.0) | 2.0 (1.5 to 3.0) | 4.0 (2.5 to 6.0) | .03 |
| Length of stay, median (IQR), d | 5.5 (4.0 to 8.0) | 4.5 (4.0 to 8.0) | 6.5 (5.0 to 8.5) | .14 |
| Wieberdink toxicity, No. (%) | .69 | |||
| Grade I | 17 (65) | 7 (70) | 10 (62) | |
| Grade III | 9 (35) | 3 (30) | 6 (38) | |
| Overall response rate (CR + PR)*, % | 79 (21 + 58) | 78 (33 + 45) | 80 (13 + 67) | .89 |
Abbreviations: CPK, creatinine phosphokinase; CR, complete response; ILI, isolated limb infusion; IQR, interquartile range; PR, partial response.